Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Exclusion of APC and VHL gene deletions by array-based comparative hybridization in two patients with microscopically visible chromosomal aberrations.

Wallerstein RJ, Brooks SS, Streck DL, Kurvathi R, Toruner GA.

Cancer Genet Cytogenet. 2007 Oct 15;178(2):151-4.

PMID:
17954272
2.

Analysis of von hippel-lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity.

Gijtenbeek JM, Jacobs B, Sprenger SH, Eleveld MJ, van Kessel AG, Kros JM, Sciot R, van Calenbergh F, Wesseling P, Jeuken JW.

J Neurosurg. 2002 Oct;97(4):977-82.

PMID:
12405390
3.

Molecular cytogenetic characterization of early and late renal cell carcinomas in von Hippel-Lindau disease.

Phillips JL, Ghadimi BM, Wangsa D, Padilla-Nash H, Worrell R, Hewitt S, Walther M, Linehan WM, Klausner RD, Ried T.

Genes Chromosomes Cancer. 2001 May;31(1):1-9.

PMID:
11284029
4.

Unintended diagnosis of Von Hippel Lindau syndrome using Array Comparative Genomic Hybridization (CGH): counseling challenges arising from unexpected information.

Hogan J, Turner A, Tucker K, Warwick L.

J Genet Couns. 2013 Feb;22(1):22-6. doi: 10.1007/s10897-012-9520-z.

PMID:
22895882
5.

Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH.

Decker HJ, Neuhaus C, Jauch A, Speicher M, Ried T, Bujard M, Brauch H, Störkel S, Stöckle M, Seliger B, Huber C.

Hum Genet. 1996 Jun;97(6):770-6.

PMID:
8641695
7.

Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.

Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.

Cancer Res. 2002 Jul 1;62(13):3803-11. Erratum in: Cancer Res. 2015 Sep 15;75(18):3993.

8.

Cytogenetic studies of 24 renal epithelial tumors with von Hippel-Lindau and fragile histidine triad protein expression correlation.

Gayrard N, Cacheux V, Iborra F, Mourad G, Argilés A.

Arch Pathol Lab Med. 2008 Jun;132(6):965-73. doi: 10.1043/1543-2165(2008)132[965:CSORET]2.0.CO;2.

PMID:
18517280
9.

Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene.

Hes F, Zewald R, Peeters T, Sijmons R, Links T, Verheij J, Matthijs G, Leguis E, Mortier G, van der Torren K, Rosman M, Lips C, Pearson P, van der Luijt R.

Hum Genet. 2000 Apr;106(4):425-31.

PMID:
10830910
10.

A de novo deletion of chromosome 5q causing familial adenomatous polyposis, dysmorphic features, and mild mental retardation.

Raedle J, Friedl W, Engels H, Koenig R, Trojan J, Zeuzem S.

Am J Gastroenterol. 2001 Oct;96(10):3016-20.

PMID:
11693343
11.

Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location.

Maranchie JK, Afonso A, Albert PS, Kalyandrug S, Phillips JL, Zhou S, Peterson J, Ghadimi BM, Hurley K, Riss J, Vasselli JR, Ried T, Zbar B, Choyke P, Walther MM, Klausner RD, Linehan WM.

Hum Mutat. 2004 Jan;23(1):40-6.

PMID:
14695531
12.

Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations.

Maher ER, Webster AR, Richards FM, Green JS, Crossey PA, Payne SJ, Moore AT.

J Med Genet. 1996 Apr;33(4):328-32.

13.

Von Hippel-Lindau syndrome. A pleomorphic condition.

Friedrich CA.

Cancer. 1999 Dec 1;86(11 Suppl):2478-82. Review.

PMID:
10630173
15.

Cytogenetic and fluorescence in situ hybridization studies on sporadic and hereditary tumors associated with von Hippel-Lindau syndrome (VHL).

Decker HJ, Klauck SM, Lawrence JB, McNeil J, Smith D, Gemmill RM, Sandberg AA, Neumann HH, Simon B, Green J, et al.

Cancer Genet Cytogenet. 1994 Oct;77(1):1-13.

PMID:
7923076
16.

[Methods for the analysis of large gene deletions and their application in some hereditary diseases].

Gergics P, Toke J, Szilágyi A, Szappanos A, Kender Z, Barta G, Tóth M, Igaz P, Rácz K, Patócs A.

Orv Hetil. 2009 Dec 13;150(50):2258-64. doi: 10.1556/OH.2009.28755. Review. Hungarian.

PMID:
19951857
17.

Characteristic chromosomal aberrations in sporadic cerebellar hemangioblastomas revealed by comparative genomic hybridization.

Sprenger SH, Gijtenbeek JM, Wesseling P, Sciot R, van Calenbergh F, Lammens M, Jeuken JW.

J Neurooncol. 2001 May;52(3):241-7.

PMID:
11519854
18.

Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter.

Zatyka M, Morrissey C, Kuzmin I, Lerman MI, Latif F, Richards FM, Maher ER.

J Med Genet. 2002 Jul;39(7):463-72.

19.

Von Hippel-Lindau (VHL) disease: an update on the clinico-pathologic and genetic aspects.

Shehata BM, Stockwell CA, Castellano-Sanchez AA, Setzer S, Schmotzer CL, Robinson H.

Adv Anat Pathol. 2008 May;15(3):165-71. doi: 10.1097/PAP.0b013e31816f852e. Review.

PMID:
18434768
20.

Second hit deletion size in von Hippel-Lindau disease.

Gläsker S, Sohn TS, Okamoto H, Li J, Lonser RR, Oldfield EH, Vortmeyer AO, Zhuang Z.

Ann Neurol. 2006 Jan;59(1):105-10.

PMID:
16261628

Supplemental Content

Support Center